DXP ENTERPRISES INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Contents
Note
NOTE 10 -INCOME TAXES
The components of income before income taxes are as follows (in thousands):
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Domestic | $110,687 | $77,309 | $79,785 |
| Foreign | 8,535 | 7,663 | 7,146 |
| Total income before taxes | $119,222 | $84,972 | $86,931 |
The provision for income taxes consisted of the following (in thousands):
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Current - | |||
| Federal | $(3,254) | $22,066 | $22,514 |
| State | 4,783 | 5,217 | 2,620 |
| Foreign | 2,194 | 2,190 | 2,044 |
| Total current | 3,723 | 29,473 | 27,178 |
| Deferred - | |||
| Federal | 26,306 | (13,597) | (7,679) |
| State | 516 | (1,347) | (1,133) |
| Foreign | — | (46) | (247) |
| Total deferred | 26,822 | (14,990) | (9,059) |
| Total current and deferred taxes | $30,545 | $14,483 | $18,119 |
The following table shows the principal reasons for the difference between the effective income tax rate and the statutory federal income tax rate:
| Years Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2025 | 2024 | 2023 | ||||
| Amount | Percent | Amount | Percent | Amount | Percent | |
| U.S. Federal Statutory Tax Rates | $25,034 | 21.0% | $17,844 | 21.0% | $18,392 | 21.2% |
| State and local income tax, net of federal (national) income tax effect(1) | 4,206 | 3.5% | 3,057 | 3.6% | 1,620 | 1.9% |
| Foreign tax effects | ||||||
| Canada | 330 | 0.3% | 433 | 0.5% | 280 | 0.3% |
| Mexico | 38 | —% | 14 | —% | 17 | —% |
| Other Foreign Jurisdictions | 55 | —% | 80 | 0.1% | — | —% |
| Effect of changes in tax laws or rates enacted in the current period | — | —% | — | —% | — | —% |
| Effect of cross-border tax laws | — | —% | — | —% | — | —% |
| Tax credits | ||||||
| Research Tax Credit | 1,339 | 1.1% | (7,333) | (8.6)% | (4,718) | (5.4)% |
| Foreign Tax Credit | — | —% | — | —% | — | —% |
| Other Tax Credits | (62) | (0.1)% | (118) | (0.1)% | (19) | —% |
| Changes in valuation allowances | — | —% | — | —% | — | —% |
| Nontaxable or nondeductible items | ||||||
| 162(m) compensation | 2,583 | 2.2% | 1,281 | 1.5% | 513 | 0.6% |
| Other nondeductible items | 1,992 | 1.7% | (460) | (0.5)% | 847 | 1.0% |
| Restricted Stock | (275) | (0.2)% | (2,056) | (2.4)% | (3) | —% |
| Earnout | — | —% | — | —% | 1,225 | 1.4% |
| Changes in unrecognized tax benefits. | (1,336) | (1.1)% | 1,732 | 2.0% | (33) | (0.2)% |
| Other Adjustments | (3,359) | (2.8)% | 9 | (0.1)% | (2) | —% |
| Effective Tax Rate | $30,545 | 25.6% | $14,483 | 17.0% | $18,119 | 20.8% |
| (1). State taxes in California, Pennsylvania, and Tennessee made up the majority (greater than 50 percent) of the tax effects in this category. | ||||||
Deferred tax liabilities and assets were comprised of the following(in thousands):
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Deferred tax assets: | ||
| Allowance for doubtful accounts | $868 | $954 |
| Inventory | 5,449 | 3,585 |
| Federal R&D credit carryforward | 1,953 | — |
| Texas R&D credit carryforward | 2,283 | 2,232 |
| Louisiana R&D credit carryforward | 10 | 10 |
| Foreign Tax Credit Carryforward | 203 | 64 |
| Charitable Contribution Carryforward | 1,225 | — |
| Net operating loss carryforward | 15,224 | 1,258 |
| Capital loss carryforward | 4 | 4 |
| Deferred Compensation | 490 | 2,304 |
| Accruals | 10,910 | 9,814 |
| Business Interest Expense Carryforward | 962 | — |
| ROU Lease Liability | 17,389 | 304 |
| Section 174 Addback | — | 40,650 |
| Total deferred tax assets | 59,672 | 63,483 |
| Less valuation allowance | (221) | (221) |
| Total deferred tax asset, net of valuation allowance | 59,451 | 63,262 |
| Deferred tax liabilities: | ||
| Goodwill | (26,252) | (24,847) |
| Intangibles | (6,322) | (7,902) |
| Property and equipment | (17,933) | (10,204) |
| ROU Asset | (17,007) | — |
| Unremitted foreign earnings | (421) | (421) |
| Method changes | (1,088) | (393) |
| Other | (802) | (243) |
| Total deferred tax liability | $(69,825) | $(44,010) |
| Net deferred tax (liability) asset | $(10,374) | $19,252 |
The Company records a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets depends on the ability to generate sufficient taxable income of the appropriate character in the future and in the appropriate taxing jurisdictions. If the Company was to determine that it would be able to realize the deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. As of December 31, 2025, the valuation allowance primarily relates to state operating loss and foreign capital loss carryforwards.
The following summarizes changes in the balance of valuation allowances on deferred tax assets(in thousands):
| December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Balance at January 1 | $(221) | $(278) | $(4) |
| Changes due to state operating loss and foreign capital loss carryforwards | — | 57 | (274) |
| Balance at December 31 | $(221) | $(221) | $(278) |
Expected tax benefit on carryforwards available for use on future income tax returns, prior to valuation allowance, at December 31, 2025, are as follows(in thousands):
| Domestic | Foreign | Expiration | |
|---|---|---|---|
| Net operating loss - foreign | $— | $543 | 2034-2045 |
| Net operating loss - federal (80%) | 13,116 | — | Indefinite |
| Net operating loss - state | 1,566 | — | 2035-Indefinite |
| Capital loss carryforward - foreign | — | 4 | Indefinite |
| Foreign tax credits | 203 | — | 2035 |
| Texas research and development tax credits | 2,283 | — | 2038-2045 |
| Louisiana research and development tax credits | 10 | — | 2026 |
Changes in the balance of unrecognized tax benefits excluding interest and penalties on uncertain tax positions are as follows(in thousands):
| December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Balance at January 1, | $(8,702) | $(5,755) | $(5,918) |
| Decreases related to prior year tax positions | 2,088 | 142 | 1,475 |
| Increases related to current year tax positions | (8) | (3,089) | (1,312) |
| Balance at December 31, | $(6,622) | $(8,702) | $(5,755) |
As of December 31, 2025, the Company had recorded a total tax benefit of $34.9 million related to federal and state research and development tax credits. This benefit is partially offset by $6.1 million uncertain tax position due to the uncertainty related to the realizability of the federal research and development tax credits. The Company is also recording a $0.5 million uncertain tax position resulting from a method change for a historical acquisition and non-deductible auto expense compensation. The total amount of these unrecognized tax benefits, if recognized, would impact the effective tax rate.
To the extent penalties and interest would be assessed on any underpayment of income tax, such accrued amounts are classified as a component of income tax provision (benefit) in the consolidated financial statements consistent with the Company's policy. For the year ended December 31, 2025, the Company recorded $0.3 million tax expense for interest and penalties related to uncertain tax positions.
The Company is subject to taxation in the U.S., various states, and foreign jurisdictions. The Company has significant operations in the U.S. and Canada and to a lesser extent in various other international jurisdictions. Tax years that remain subject to examination vary by legal entity but are generally closed in the U.S. for the tax years prior to 2015 and outside the U.S. for the tax years ended prior to 2019. There is a 4-year statute of limitations for Canadian returns based on the date tax assessment is received, not filing date. Tax assessments are typically received within weeks of filing date.
Income taxes paid net of refunds are as follows (in thousands):
| Years Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Federal | $29,620 | $11,958 | $15,289 |
| State | |||
| California (1) | 567 | 1,309 | 21 |
| Other States | 3,784 | 3,838 | 3,379 |
| Foreign | |||
| Canada | 2,174 | 1,318 | 1,617 |
| Other Foreign Jurisdictions | 254 | 258 | 257 |
| Total Income Taxes Paid (net of refunds) | $36,399 | $18,681 | $20,563 |
| '(1) For 2025 and 2023, California did not exceed the 5% threshold; however, the total has been separately stated for comparability. | |||
NOTE 11 -SHARE-BASED COMPENSATION
2016 Omnibus Incentive Plan
On June 16, 2023, our shareholders approved an amendment to the DXP Enterprises, Inc. 2016 Omnibus Incentive Plan (the “2016 Plan”) to increase the number of shares that can be issued under the 2016 Plan from 1,000,000 shares to a total of 1,250,000 shares, which represents an increase of 250,000 shares (the “Amendment”), which authorized grants of restricted stock awards, restricted stock units, performance awards, options, investment rights, and cash-based awards.
Restricted Stock Awards
The Company grants restricted stock awards (“RSAs”) to employees and non-employee directors. RSAs qualify as participating securities as each award contains non-forfeitable rights to dividends. RSAs are considered outstanding at the date of grant. Refer to Note. 12 Earnings Per Sharefor further detail.
RSAs are subject to vesting periods betweenone toten years. Compensation expense for RSAs is calculated based on the closing price of the Company’s common stock at the date of grant and recognized over the requisite vesting period on a straight-line basis. Unvested RSAs may be forfeited if employees or non-employee directors cease employment or services during the requisite vesting period. Forfeitures reduce expense at the time employment or service cease at the original grant date value. The Company issues new shares of common stock, if available, to settle vested RSAs. At December 31, 2025,316,163 shares were available for grant.
Changes in RSAs for the twelve months ended December 31, 2025 are as follows:
| Number ofShares | Weighted AverageGrant Price | |
|---|---|---|
| Non-vested at December 31, 2024 | 302,400 | $38.11 |
| Granted | 57,275 | $89.87 |
| Forfeited | (2,478) | $40.34 |
| Vested | (151,486) | $35.73 |
| Non-vested at December 31, 2025 | 205,711 | $54.25 |
Changes in RSAs for the twelve months ended December 31, 2024 are as follows:
| Number ofShares | Weighted AverageGrant Price | |
|---|---|---|
| Non-vested at December 31, 2023 | 304,437 | $27.60 |
| Granted | 127,860 | $52.89 |
| Forfeited | (9,644) | $26.96 |
| Vested | (120,253) | $28.13 |
| Non-vested at December 31, 2024 | 302,400 | $38.11 |
Changes in RSAs for the twelve months ended December 31, 2023 are as follows:
| Number ofShares | Weighted AverageGrant Price | |
|---|---|---|
| Non-vested at December 31, 2022 | 157,767 | $28.64 |
| Granted | 215,554 | $27.36 |
| Forfeited | — | $— |
| Vested | (68,884) | $29.23 |
| Non-vested at December 31, 2023 | 304,437 | $27.60 |
The following table sets forth information regarding the vesting and distribution of RSAs for the periods indicated (in thousands):
| December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Aggregate grant-date fair value of vested shares | $5,412 | $3,382 | $2,013 |
| Tax benefits realized for tax deductions related to vestings | 1,462 | 803 | 756 |
| Compensation expense associated with RSAs recognized during the period | 5,708 | 4,714 | 3,072 |
Unrecognized compensation expense under the 2016 Plan at December 31, 2025, December 31, 2024 and December 31, 2023 was $6.9 million, $7.7 million and $5.9 million, respectively. As of December 31, 2025, the weighted average period over which the unrecognized compensation expense is expected to be recognized is 1.2 years.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.